Compounds

Details Compounds Compounds

2007-02-13

2007-02-13

Navarro, Mark (Department: 1645)

Organic compounds -- part of the class 532-570 series

Organic compounds

Carbohydrates or derivatives

C435S252300, C435S320100

Reexamination Certificate

active

11166905

ABSTRACT:
This invention relates to newly identified Staphylococcal polynucleotides, polypeptides encoded by such polynucleotides, the uses of such polynucleotides and polypeptides, as well as the production of such polynucleotides and polypeptides and recombinant host cells transformed with the polynucleotides. This invention also relates to inhibiting the biosynthesis or action of such polynucleotides or polypeptides and to the use of such inhibitors in therapy.

REFERENCES:
patent: 5302527 (1994-04-01), Birkett et al.
patent: 5539132 (1996-07-01), Royer et al.
patent: 5614551 (1997-03-01), Dick et al.
patent: 5759837 (1998-06-01), Kuhajda et al.
patent: 5965402 (1999-10-01), Black et al.
patent: 6228619 (2001-05-01), Foster et al.
patent: 6274376 (2001-08-01), Black et al.
patent: 6380370 (2002-04-01), Doucette-Stamm et al.
patent: 6403337 (2002-06-01), Bailey et al.
patent: 6432670 (2002-08-01), Payne et al.
patent: 6593114 (2003-07-01), Kunsch et al.
patent: 6753172 (2004-06-01), Black et al.
patent: 6821746 (2004-11-01), DeWolf, Jr. et al.
patent: 6951729 (2005-10-01), Dewolf et al.
patent: 6995254 (2006-02-01), Payne et al.
patent: 7033795 (2006-04-01), DeWolf, Jr. et al.
patent: 7048926 (2006-05-01), Brandt et al.
patent: 2002/0076766 (2002-06-01), Black et al.
patent: 2004/0053814 (2004-03-01), Brandt et al.
patent: 2005/0032161 (2005-02-01), Black et al.
patent: DT 26 20 777 (1977-12-01), None
patent: 0 78 6519 (1997-07-01), None
patent: 0 826 774 (1998-04-01), None
patent: 10-174590 (1998-06-01), None
patent: WO 97/30070 (1997-08-01), None
patent: WO 97/30149 (1997-08-01), None
patent: WO 00/70017 (2000-11-01), None
patent: WO 01/30988 (2001-05-01), None
patent: WO 01/48248 (2001-07-01), None
patent: WO 02/31128 (2002-04-01), None
Bergler et al., “Protein EnvM is the NADH-dependent Enoyl-ACP Reductase (Fabl) ofEscherichia coli*”, The Journal of Biological Chemistry,vol. 269, No. 8, pp. 5493-5496 (1994).
Bergler et al., “Sequences of theenvMgene and of two mutated alleles inEscherichia coli”,Journal of General Microbiology (1992), 138, pp. 2093-2100.
Broadwater et al., “Spinach Hoto-Acyl Carrier Protein: Overproduction and Phosphopantetheinylation inEscherichia coliBL21 (DE3),in VitroAcylation, and Enzymatic Desaturation of Histidine-Tagged Isoform 11”, Protein Expression and Purification 15, 314-326 (1999).
Edwards, et al., “Cloning of the fabF gene in an expression vector and in vitro characterization of recombinantfabFandfabBencoded enzymes fromEscherichia coli”, FEBS Letters,402:62-66 (1997).
Grassberger et al., “Preparation and Antibacterial Activates of New 1,2,3-Diazaborine Derivatives and Analogues”, Journal of Medicinal Chemistry, 1984. vol. 24, No. 8, pp. 947-953.
Gronowitz et al., “Antibacterial borazaro derivatives”, Acta Pharm. Suecica 8, pp. 377-390 (1971).
Heath et al., “Enoyl-Acyl Carrier Protein Reductase (fabl) Plays a Determinant Role in Completing Cycles of Fatty Acid Elongation inEscherichia coli*”,The Journal of Biological Chemistry, vol. 270, No. 44, pp. 26538-26542 (1995).
Heath et al., “Regulation of Fatty Acid Elongation and Initiation by Acyl-Acyl Carrier Protein inEscherichia coli*”,The Journal of Biological Chemistry, vol. 271, No. 4, pp. 1833-1836 (1996).
Lam et al., “Effect of diazaborine derivative (Sa 84.474) on the virulence ofEscherichia coli”, Journal of Antimicrobial Chemotherapy (1987) 20, pp. 37-45.
Lambalot, et al., “Cloning, Over production, and Characterization of theEscherichia coliHalo-acyl Carrier Protein Synthase*”, The Journal of Biological Chemistry, vol. 270, No. 42, pp. 24658-24661 (1995).
Ngo et al., “Computational complexity, protein structure prediction, and the Levinthal paradox”, Chapter 14 in ‘The Protein Folding Problem and Tertiary Structure Prediction’, Merz et al. (eds.), Birkhauser: Boston, MA, pp. 433 & 492-495.
Rock et al., “Preparative Enzymatic Synthesis and Hydrophobic Chromatography of Acyl-Acyl Carrier Protein”,The Journal of Biological Chemistry,254(15):7123-7128 (1979).
Rock et al., “Acyl Carrier Protein fromEscherichia coli”, Methods in Enzymology,71:341-351 (1981).
Roujeinkova et al., “Inhibitor Binding Studies on Enoyl Reductase Reveal Conformational Changes Related to Substrate Recognition”,The Journal of Biological Chemistry,274(43): 30811-30817 (1999).
Turnowsky et al., “envM genes ofSalmonella typhimuriumandEscherichia coli”, Journal of Bacteriology, Dec. 1989 pp. 6555-6565.
Ward et al., “Kinetic and Structural Characteristics of the Inhibition of Enoyl (Acyl Carrier Protein) Reductase by Triclosan”, Biochemistry, 38: 12514-12525 (1999).
U.S. Appl. No. 10/407,028, filed Apr. 4, 2003, Methods of Agonizing and Antagonizing Fab K.
U.S. Appl. No. 11/166,905, filed Jun. 23, 2005, Novel Compounds.
U.S. Appl. No. 09/292,411, filed Apr. 15, 1999, Fab I.
U.S. Appl. No. 09/292,412, filed Apr. 15, 1999, Polynucleotides Encoding Staphyloccal Fab I Enoyl-Acp Reductase (as Amended).
U.S. Appl. No. 10/089,019, filed Oct. 26, 2000, Methods for Making and Using Fatty Acid Synthesis Pathway Reagents.

Affiliated with

Also associated with

Rating

Compounds does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Compounds, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compounds will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3879619